Myositis, Inclusion Body clinical trials
The registry lists 65 studies for Myositis, Inclusion Body across more than 10 countries. 10 are recruiting or about to start. 45 of them are mainly about Myositis, Inclusion Body (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Myositis, Inclusion Body studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (6) · LMU Klinikum (5) · University of Kansas Medical Center (4) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Assistance Publique - Hôpitaux de Paris (3) · Abcuro, Inc. (3) · ZevraDenmark (2) · Karolinska Institutet (2)
What is being tested here
Drugs under test in Myositis, Inclusion Body studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Dec 2026IBM Dietary Surveillance Study · Manchester Metropolitan University
- Mar 2027Sporadic Inclusion Body Myositis Natural History Study · University of California, Irvine
- May 2027The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. · LMU Klinikum
- May 2027Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis · Austin Neuromuscular Center
- Aug 2027Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders · LMU Klinikum
Who these studies take
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 (67%) set no upper age limit and 1 (17%) stop at 75 or younger. 2 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (33%) | 2 (33%) |
| 18 | 4 (67%) | 4 (67%) |
| 30 | 4 (67%) | 4 (67%) |
| 40 | 4 (67%) | 4 (67%) |
| 50 | 6 (100%) | 6 (100%) |
| 65 | 6 (100%) | 6 (100%) |
| 75 | 6 (100%) | 6 (100%) |
| 85 | 5 (83%) | 5 (83%) |
Across all 65 studies, recruiting or not: 25% stop at 75 or younger and 14% at 65; 11% take children; 0% are for women only and 6% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 65. Browse all 65 → or search them.
- Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body MyositisRecruitingNCT078231011 country
- Adult and Juvenile MyositisRecruitingNCT000179141 country
- Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
- Ruxolitinib Treatment in Inclusion Body MyositisRecruitingNCT06536166Phase 21 country
- IBM Dietary Surveillance StudyNot yet recruitingNCT075359961 country
- MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)RecruitingNCT073741071 country
- Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisRecruitingNCT06479863Early Phase 11 country
- Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular DisordersEnrolling by invitationNCT066056121 country
- The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.Enrolling by invitationNCT07072676Not applicable1 country
- Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe DiseaseRecruitingNCT052729691 country
- Environmental Risk Factors for Myositis in Military PersonnelCompletedNCT017343691 country
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseActive, not recruitingNCT07478172Not applicable1 country
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body MyositisCompletedNCT05721573Phase 2/37 countries
- The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each ConditionActive, not recruitingNCT077967761 country
- Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over TimeActive, not recruitingNCT061531081 country
- Sporadic Inclusion Body Myositis Natural History StudyActive, not recruitingNCT050468211 country
- Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory MyopathiesCompletedNCT01432613Not applicable1 country
- Phase III Trial of Sirolimus in IBMActive, not recruitingNCT04789070Phase 33 countries
- Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative CellsCompletedNCT04975841Not applicable1 country
- Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisCompletedNCT02481453Phase 2/31 country
- Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisActive, not recruitingNCT06450886Phase 2/32 countries
- Exercise as Treatment for Patients With Inclusion Body MyositisCompletedNCT06644482Not applicable1 country
- A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients with (IBM)CompletedNCT04659031Phase 11 country
- Safety and Tolerability of Phenylbutyrate in Inclusion Body MyositisCompletedNCT04421677Phase 11 country
- The Risk of Falls Index for Patients With Neuromuscular DisordersCompletedNCT058908331 country
- Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained RowersCompletedNCT06133751Phase 41 country
- Study and Treatment of Inflammatory Muscle DiseasesCompletedNCT000012651 country
- Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body MyositisCompletedNCT01519349Phase 11 country
- Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension TrialTerminatedNCT04049097Phase 32 countries
- The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and ErythropoiesisCompletedNCT05880030Not applicable
- Study of Arimoclomol in Inclusion Body Myositis (IBM)CompletedNCT02753530Phase 22 countries
- Investigating Genes in Patients With Polymyositis and DermatomyositisActive, not recruitingNCT011715731 country
- Molecular Profile of the Evolution of Inclusion Body MyositisCompletedNCT03299335Not applicable1 country
- Cell Therapy for IBM by Muscle Injection of ADSVFStatus unknownNCT05032131Phase 11 country
- Musculoskeletal Nociceptive Pain in Participants With Neuromuscular DisordersCompletedNCT049071621 country
- Study of Pioglitazone in Sporadic Inclusion Body MyositisCompletedNCT03440034Phase 11 country
- Efficacy and Tolerability of BAF312 in Patients With PolymyositisTerminatedNCT01801917Phase 26 countries
- Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT02250443Phase 2/31 country
- Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT01423110Phase 21 country
- Establishing Muscle Impedance Parameters With Electrical Impedance MyographyCompletedNCT036333181 country
- Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained MenCompletedNCT03760757Not applicable1 country
- Acceptance and Commitment Therapy for Muscle DiseaseCompletedNCT02810028Not applicable1 country
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisWithdrawnNCT03710941Phase 2
- Efficacy and Tolerability of BAF312 in Patients With Polymyositis and DermatomyositisTerminatedNCT01148810Phase 25 countries
- Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older AdultsStatus unknownNCT03743675Not applicable1 country
- An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203CompletedNCT02573467Phase 310 countries
- Protein Supplementation and Muscle Recovery in FootballCompletedNCT03348267Not applicable1 country
- Safety and Efficacy of a Flavonoids- and omega3s-based Compound for the Treatment of Muscular DystrophiesCompletedNCT03317171Not applicable1 country
- Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsCompletedNCT01925209Phase 2/310 countries
- Immune Abnormalities in Sporadic Inclusion Body MyositisCompletedNCT000302121 country